|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
207.22(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,592,266 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$56,317,001 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
60 |
103 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nsv Partners Iii Gp Llc |
|
|
2023-07-11 |
4 |
AS |
$37.54 |
$1,075,411 |
D/D |
(28,646) |
8,560,141 |
|
-94% |
|
Subramaniam Somu |
|
|
2023-07-11 |
4 |
AS |
$37.54 |
$1,075,411 |
I/I |
(28,646) |
8,560,141 |
|
-94% |
|
Subramaniam Somu |
|
|
2023-07-07 |
4/A |
AS |
$0.00 |
$0 |
I/I |
(964,178) |
8,588,787 |
|
- |
|
Subramaniam Somu |
|
|
2023-07-07 |
4/A |
AS |
$34.99 |
$3,523,057 |
I/I |
(100,000) |
9,552,965 |
|
- |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-07 |
4/A |
AS |
$0.00 |
$0 |
I/I |
(964,178) |
8,588,787 |
|
- |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-07 |
4/A |
AS |
$35.82 |
$874,963 |
I/I |
(24,314) |
9,552,965 |
|
- |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-07 |
4/A |
AS |
$34.99 |
$2,648,094 |
I/I |
(75,686) |
9,577,279 |
|
- |
|
Subramaniam Somu |
|
|
2023-07-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,030,341) |
8,522,624 |
|
- |
|
Subramaniam Somu |
|
|
2023-07-07 |
4 |
S |
$34.99 |
$3,523,057 |
I/I |
(100,000) |
9,552,965 |
|
93% |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,030,341) |
8,522,624 |
|
- |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-07 |
4 |
S |
$34.99 |
$3,523,057 |
D/D |
(100,000) |
9,552,965 |
|
93% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-07-05 |
4 |
AS |
$37.74 |
$1,151,227 |
D/D |
(30,000) |
1,512,911 |
|
-93% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-07-05 |
4 |
OE |
$8.04 |
$239,471 |
D/D |
29,785 |
1,542,911 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-07-03 |
4 |
S |
$35.48 |
$5,229,698 |
I/I |
(134,080) |
9,652,965 |
|
93% |
|
Subramaniam Somu |
Director |
|
2023-07-03 |
4 |
S |
$35.48 |
$5,229,698 |
I/I |
(134,080) |
9,652,965 |
|
93% |
|
Nuss John |
Chief Scientific Officer |
|
2023-07-03 |
4 |
AS |
$33.54 |
$791,637 |
D/D |
(20,000) |
244,815 |
|
-93% |
|
Nuss John |
Chief Scientific Officer |
|
2023-07-03 |
4 |
OE |
$0.20 |
$4,000 |
D/D |
20,000 |
264,815 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-07-03 |
4 |
AS |
$33.57 |
$588,343 |
D/D |
(15,000) |
276,548 |
|
-93% |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-07-03 |
4 |
OE |
$0.20 |
$11,538 |
D/D |
15,000 |
291,548 |
|
- |
|
Sandborn William J. |
See Remarks |
|
2023-07-03 |
4 |
AS |
$40.00 |
$139,480 |
I/I |
(3,487) |
27,688 |
|
-93% |
|
Sandborn William J. |
See Remarks |
|
2023-07-03 |
4 |
AS |
$40.00 |
$476,014 |
D/D |
(11,900) |
48,389 |
|
-93% |
|
Sandborn William J. |
See Remarks |
|
2023-07-03 |
4 |
OE |
$14.85 |
$176,715 |
D/D |
11,900 |
60,289 |
|
- |
|
Sandborn William J. |
See Remarks |
|
2023-06-23 |
4 |
AS |
$32.10 |
$352,844 |
D/D |
(10,790) |
48,389 |
|
-56% |
|
Sandborn William J. |
See Remarks |
|
2023-06-23 |
4 |
OE |
$0.20 |
$2,158 |
D/D |
10,790 |
59,179 |
|
- |
|
Sandborn William J. |
See Remarks |
|
2023-06-15 |
4 |
AS |
$33.88 |
$119,092 |
I/I |
(3,487) |
31,175 |
|
-53% |
|
178 Records found
|
|
Page 3 of 8 |
|
|